Would like to have some spare $'s, as the momentum is definitely positive. Admittedly they are spending more money, though it is a necessity as they grow their footprint to service foreign markets, and have product available in these jurisdictions. R&D grant was a large percentage of cash flow, and forecast ineligibility for FY21 should be offset by the gain in sales revenue. Management appear to have a downbeat forward forecast, but are positioning for growth with the supply partnerships they are building.
Ann: Half Yearly Report and Accounts, page-3
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $136.1M | |||
| Open | High | Low | Value | Volume |
| 75.0¢ | 77.0¢ | 72.5¢ | $69.56K | 94.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17985 | 67.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 74.0¢ | 5500 | 1 |
View Market Depth
| Last trade - 15.13pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
75.0¢ |
Change
0.000 ( 3.45 %) |
||||
| Open | High | Low | Volume | ||
| 76.5¢ | 77.0¢ | 73.5¢ | 14619 | ||
| Last updated 14.11pm 30/05/2024 ? | |||||
| GSS (ASX) Chart |